Clinical trials: Soft Tissue Sarcoma (STS)
Osteosarcoma, Soft Tissue Sarcoma (STS)
ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on bone and soft tissue sarcoma.
- Trial name
- NCT06699576
- Testing
- HS-20093, Anlotinib, Epirubicin
- Volunteers
- 448 people
- Sponsor
- Hansoh BioMedical R&D Company
Osteosarcoma Metastatic, Soft Tissue Sarcoma (STS)
A Study to Assess Safety and Efficacy of SOT106 in Patients With LRRC15-positive Advanced Unresectable or Metastatic Osteosarcoma or Soft Tissue Sarcoma
SOT106 is a special cancer medicine designed to find and kill certain cancer cells that carry a marker called LRRC15, while causing less harm to healthy cells. The study consists of two parts, Part A and Part B.
- Conditions
- Osteosarcoma Metastatic, Soft Tissue Sarcoma (STS), Osteosarcoma, Advanced
- Trial name
- NCT07801222
- Testing
- SOT106
- Where
- Moldova
- Volunteers
- 70 people
- Sponsor
- SOTIO Biotech a.s.
Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of DCC-2618, administered…
- Conditions
- Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis, Advanced Cancers
- Trial name
- NCT02571036
- Testing
- DCC-2618
- Where
- 26 sites in United States, Canada and 4 more
- Volunteers
- 282 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Soft Tissue Sarcoma (STS), Utidelone
Utidelone Capsules Combined With Doxorubicin for Advanced Soft Tissue Sarcoma
This trial is an open, multicenter, phase II clinical trial evaluating the efficacy and safety of uterostatin capsules (UTD2) combined with doxorubicin and tislelizumab in the treatment of advanced soft tissue sarcoma.
- Conditions
- Soft Tissue Sarcoma (STS), Utidelone, Doxorubicin
- Trial name
- NCT07842276
- Testing
- UTD2 + tislelizumab + doxorubicin
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
Soft Tissue Sarcoma
A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma
The purpose of this study is to evaluate the safety of olaratumab plus pembrolizumab in participants with previously treated advanced or metastatic soft tissue sarcoma.
- Trial name
- NCT03126591
- Testing
- Olaratumab, Pembrolizumab (KEYTRUDA®)
- Where
- 6 sites in United States, Belgium and 2 more
- Volunteers
- 41 people
- Sponsor
- Eli Lilly and Company
Sarcoma,Soft Tissue, Pulmonary Metastasis
Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases
This is a multi-center, open-label, single-arm study that in Phase 1b will determine the maximum tolerated dose (MTD)/ recommended phase 2 dose (RP2D) and safety of L-Annamycin and in Phase 2 will explore the efficacy of L…
- Trial name
- NCT04887298
- Testing
- Liposomal Annamycin (L-Annamycin)
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Moleculin Biotech, Inc.
Endometrial Neoplasms, Soft Tissue Sarcoma (STS)
A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers
This phase 1b/2a study evaluates AL58805, an oral investigational drug that blocks PI3K and mTOR signaling, in combination with one of three anticancer treatments: AL8326 (veonetinib), eribulin, or fulvestrant.
- Conditions
- Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
- Trial name
- NCT07811232
- Testing
- AL58805, AL8326, Eribulin
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- Advenchen Pharmaceuticals, LLC.
Metastatic Adult Soft Tissue Sarcoma
Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas.
The main objective of the trial is to document the preliminary antitumor activity of two doses of NGR-hTNF administered either alone or in combination with doxorubicin in locally advanced or metastatic soft-tissue sarcoma (STS)…
- Trial name
- NCT00484341
- Testing
- low-dose NGR-hTNF, high-dose NGR-hTNF, Doxorubicin
- Where
- 7 sites in France, Italy and 1 more
- Volunteers
- 69 people
- Sponsor
- AGC Biologics S.p.A.
Small Cell Lung Cancer, Soft Tissue Sarcoma
Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.
Tinostamustine (EDO-S101) is a first-in-class alkylating deacetylase inhibitor designed to improve drug access to deoxyribonucleic acid (DNA) strands, induce DNA damage and counteract its repair in cancer cells.
- Conditions
- Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer
- Trial name
- EDO-S101 (NCT03345485)
- Testing
- Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min
- Where
- 13 sites in United States, Canada and 3 more
- Volunteers
- 71 people
- Sponsor
- Mundipharma Research Limited
Leiomyosarcoma
Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)
The present study is an open-label, randomized, controlled, two-arm multi-center study of the efficacy of L19TNF treatment in combination with doxorubicin versus doxorubicin alone in metastatic leiomyosarcoma patients.
- Trial name
- FIBROSARC US (NCT03420014)
- Testing
- Doxorubicin, L19TNF plus doxorubicin
- Where
- 8 sites in United States
- Volunteers
- 114 people
- Sponsor
- Philogen S.p.A.
Advanced Solid Tumor, Metastatic Solid Tumor
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT05824975
- Testing
- GI-102 subcutaneous (SC), GI-102, doxorubicin
- Where
- 11 sites in United States, South Korea
- Volunteers
- 358 people
- Sponsor
- GI Innovation, Inc.
Sarcoma, Soft Tissue
Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma
Pazopanib monotherapy is approved by the Food and Drug Administration (FDA), European Medicines Agency, and other regulatory authorities worldwide for the treatment of patients with advanced renal cell carcinoma and patients with…
- Trial name
- NCT02367651
- Testing
- Pazopanib 800 mg
- Sponsor
- GlaxoSmithKline
Sarcoma, Soft Tissue Sarcoma (STS)
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma
A study of lifileucel (tumor-infiltrating lymphocytes) in adults with advanced soft tissue sarcoma ('SARATOGA')
- Conditions
- Sarcoma, Soft Tissue Sarcoma (STS), Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS)
- Trial name
- 'SARATOGA' (NCT07741877)
- Testing
- Lifileucel
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Soft Tissue Sarcoma
Study in Patients With Advanced Soft Tissue Sarcoma (STS) After Failure of Anthracyclines and/or Ifosfamide
This is an observational, non-randomized, open label, multicenter, phase IV study, which aims to reflect a real-life practice routinely used for the management of advanced soft tissue sarcoma after failure of anthracyclines…
- Trial name
- NCT01299506
- Where
- 5 sites in Netherlands
- Volunteers
- 102 people
- Sponsor
- PharmaMar
Gastrointestinal Stromal Tumors, Soft Tissue Sarcomas
Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)
The primary objectives of the study are: Determine the safety and maximum tolerated dose (MTD) of IPI-504 in GIST and STS patients who have failed prior therapies Recommend a dose for subsequent studies of IPI-504
- Trial name
- NCT00276302
- Testing
- IPI-504
- Where
- 5 sites in United States, Canada
- Volunteers
- 63 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Advanced Soft Tissue Sarcoma
A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
The purpose of the phase 1b portion is to evaluate safety and tolerability and determine a recommended phase 2 dose for TRC105 when added to standard dose pazopanib in patients with advanced soft tissue sarcoma.
- Trial name
- NCT01975519
- Testing
- TRC105 and Pazopanib
- Where
- 9 sites in United States
- Volunteers
- 111 people
- Sponsor
- Tracon Pharmaceuticals Inc.